Yahoo Finance Insider Sale: Director David Guyer Sells Shares of EyePoint Pharmaceuticals Inc (EYPT)
On May 14, 2024, David Guyer, Director at EyePoint Pharmaceuticals Inc (NASDAQ:EYPT), executed a sale of 11,625 shares of the company. The transaction was filed on the same day with the SEC. Following this transaction, the insider has sold a total of 11,625 shares over the past year, with no recorded purchases.
EyePoint Pharmaceuticals Inc (NASDAQ:EYPT) is a biopharmaceutical company focused on developing and commercializing therapeutics for eye diseases. The company's products are designed to treat serious eye disorders in a way that improves upon the standard of care and delivers significant clinical benefits to patients.
On the date of the transaction, shares of EyePoint Pharmaceuticals Inc were priced at $12.65. This pricing gives the company a market cap of approximately $652.096 million.
The sale by the insider occurs in a context where EyePoint Pharmaceuticals Inc has experienced a significant number of insider transactions over the past year. There have been 5 insider buys and 25 insider sells during this period.
Regarding the company's valuation, EyePoint Pharmaceuticals Inc has a price-to-GF Value ratio of 1.69, indicating that the stock is Significantly Overvalued according to the GF Value. The GF Value is calculated based on historical multiples such as price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, along with a GuruFocus adjustment factor and future business performance estimates from analysts.
The insider's recent transaction provides an important data point for investors and market watchers, reflecting the ongoing financial activities within EyePoint Pharmaceuticals Inc.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
This article first appeared on GuruFocus.
